<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754087</url>
  </required_header>
  <id_info>
    <org_study_id>CMG2019-32H</org_study_id>
    <nct_id>NCT04754087</nct_id>
  </id_info>
  <brief_title>G7 With Vivacit-E and Longevity Post-market Follow-up Study</brief_title>
  <official_title>Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners &amp; Instrumentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to confirm the long-term safety, performance, and&#xD;
      clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity&#xD;
      HXLPE liners and instrumentation in primary and revision total hip arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is defined by the survival of the implant system at 10 years, which is&#xD;
      based on removal or intended removal of the study device and will be determined using Kaplan&#xD;
      Meier method. The safety of the system will be assessed by monitoring the frequency and&#xD;
      incidence of adverse events. Relation of the events to either implant or instrumentation&#xD;
      should be specified.&#xD;
&#xD;
      The secondary endpoints are the assessment of performance and clinical benefits by recording&#xD;
      patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if&#xD;
      available).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2033</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2033</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival of the study device (liner); whether or not it is still implanted in the subject</measure>
    <time_frame>At 10 years</time_frame>
    <description>Survivorship will be based on revision or intended revision of the study device (liner).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event (safety)</measure>
    <time_frame>At 10 years</time_frame>
    <description>Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and Function using Modified Harris Hip Score</measure>
    <time_frame>At 10 years</time_frame>
    <description>Pain and function will be measured using the Modified Harris Hip Score self assessment. The overall score runs from 0-100 with 100 representing the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and Function using Oxford Hip Score</measure>
    <time_frame>At 10 years</time_frame>
    <description>Pain and function will be measured using the Oxford Hip Score self assessment. The overall score runs from 0-48 with 48 representing the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life using EQ-5D-5L Descriptive System</measure>
    <time_frame>At 10 years</time_frame>
    <description>Perceived qualify of life will be measured using the EQ-5D-5L Descriptive System - comprises mobility, self care, usual activities, pain/discomfort, anxiety/depression. Each question in this section has an overall score of 1-5 with 1 representing the best health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life using EQ-5D-5L EQ visual analogue scale</measure>
    <time_frame>At 10 years</time_frame>
    <description>Perceived qualify of life will be measured using the EQ visual analogue scale (EQ VAS) - records the respondent's self-rated health on a vertical, visual analogue scale. This section has an overall score of 0-100 with 100 representing the best health.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <condition>Degenerative Joint Disease of Hip</condition>
  <condition>Avascular Necrosis of Hip</condition>
  <condition>Rheumatoid Arthritis of Hip</condition>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Osteoarthritis of Hip</condition>
  <condition>Fractures, Hip</condition>
  <condition>Fracture of Hip</condition>
  <arm_group>
    <arm_group_label>G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivacit-E and Longevity (HXLPE) Liners</intervention_name>
    <description>This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.</description>
    <arm_group_label>G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be a legal adult who has reached full skeletal maturity.&#xD;
&#xD;
          -  Patient must be treated for one of the following indications:&#xD;
&#xD;
          -  Noninflammatory degenerative joint disease including osteoarthritis and avascular&#xD;
             necrosis&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Correction of functional deformity&#xD;
&#xD;
          -  Treatment of non-union, femoral neck fracture, and trochanteric fractures of the&#xD;
             proximal femur with head involvement, unmanageable by other techniques&#xD;
&#xD;
          -  Revision procedures where other treatment or devices have failed&#xD;
&#xD;
          -  Patient must be able and willing to complete the protocol required follow-up visits.&#xD;
&#xD;
          -  Patient must be able and willing to sign the Institutional Review Board or Ethics&#xD;
             Committee (IRB/EC) approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presents with osteoporosis, which in the opinion of the Principal&#xD;
             Investigator, may limit the subject's ability to support total hip arthroplasty using&#xD;
             the study device.&#xD;
&#xD;
          -  Patient has a metabolic disorder that may impair bone formation.&#xD;
&#xD;
          -  Patient has osteomalacia.&#xD;
&#xD;
          -  Patient has distant foci of infections which may spread to the implant site or patient&#xD;
             with infection, sepsis or osteomyelitis.&#xD;
&#xD;
          -  Patient has rapid joint destruction, marked bone loss or bone resorption apparent on&#xD;
             roentgenogram.&#xD;
&#xD;
          -  Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease&#xD;
&#xD;
          -  Patient is a prisoner.&#xD;
&#xD;
          -  Patient is a current alcohol or drug abuser.&#xD;
&#xD;
          -  Uncooperative patient or patient with neurologic disorders who is incapable or&#xD;
             unwilling to follow directions.&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kacy Arnold, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy J Hatcher, BS</last_name>
    <phone>574-549-4281</phone>
    <email>wendy.hatcher@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Boylan, MBA</last_name>
    <phone>574 527 7934</phone>
    <email>Ryan.Boylan@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado Joint Replacement</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Ernevad</last_name>
      <phone>303-765-3703</phone>
      <email>evakarinernevad@centura.org</email>
    </contact>
    <investigator>
      <last_name>Todd M Miner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Bend Orthopaedics</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Yocum, PhD</last_name>
      <phone>574-247-5199</phone>
      <email>dyocum@sbortho.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey D Yergler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Friend</last_name>
      <phone>919-668-4373</phone>
      <email>jennifer.friend@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Thorsten M Seyler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael P Bolognesi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slocum Center for Orthopedics &amp; Sports Medicine</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Headlee</last_name>
      <phone>541-868-3217</phone>
      <email>cindy.headlee@slocumfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Steven N Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenna Blackburn, PhD MPH</last_name>
      <phone>859-533-5996</phone>
      <email>Brenna.Blackburn@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy M Gililland</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher L Peters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher E Pelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Archibeck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

